John Q Walker, Ph.D., the Co-founder, and Chief Technology Officer of uMethod Health, recently participated in a distinguished panel of experts in the field of disease. The discussion centered around translating technological advancements into actionable strategies at a clinical level. Together, the panel delved into the realm of proactive, precision, and holistic medicine, identifying it as the next frontier in healthcare. Dr. Walker describes how uMethod is at the forefront…READ MORE

Cognitive decline is multi-factorial but rarely treated as such due to clinical complexity of the process. Emerging data driven systems with assistive-AI enable physicians to deliver comprehensive and personalized care at scale. Vik's session introduces uMETHOD's RestoreU solution, a software based service which is helping transform care of cognitive decline and its costs to society. The solution is available nationwide through several diagnostic lab service providers. To view Vik's discussion…READ MORE

…READ MORE

Alzheimer’s is a disease of data. The disease doesn’t have what we typically react to quickly: There is no pain, no blood, no pus, no rash, no dry mouth, nothing is visibly out of kilter.  Yet, Alzheimer’s disease generally starts its destruction 20 years before symptoms (most notably memory loss) are acknowledged. There can be more than 50 treatable causes to be dealt with simultaneously. More than half of the…READ MORE

RESEARCH TRIANGLE PARK – Triangle Tweener Fund continues to provide fuel for the region’s startup ecosystem, cranking out 18 investments and adding 14 additional companies to its portfolio in the last three months. “This is up 20% year over year deal wise and 30% investment wise,” says Tweener fund founder and serial entrepreneur Scot Wingo. The fund was established last year and targets startups headquartered in the Research Triangle Park. So far…READ MORE

RESEARCH TRIANGLE PARK –  Alzheimer’s Disease and dementia have long been feared by many, especially those with first-hand experience. Vik Chandra, CEO and co-founder of uMETHOD is familiar with this disease having seen it in both his grandmother and mother-in-law. According to Chandra, there are 17 and a half million Medicare-aged patients somewhere on a spectrum of cognitive decline, and about 150,000 doctors across the country caring for these patients. He is passionate…READ MORE

Quest Diagnostics recently announced the nationwide availability of the RestoreU Dementia Panel, an artificial intelligence (AI)-based risk assessment and care service created by uMETHOD Health. In this video interview, Dr. Michael K. Racke, medical director for neurology at Quest Diagnostics, spoke to Stephen Wellman, director of content and strategy at LabPulse and The Science Advisory Board, about the challenges associated with identifying those who do not have Alzheimer's and may…READ MORE

More than six million Americans are living with Alzheimer’s disease — and one in three seniors dies with the disease, according to statistics from the Alzheimer’s Association. With so many different factors — genetics, lifestyle and environment — influencing a person’s risk of developing Alzheimer’s, many doctors are moving away from one-size-fits-all approaches and calling for more individualized treatments. It’s a concept known as precision medicine. And it’s what inspired a…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

uMETHOD Health is a technology company in Research Triangle Park, North Carolina, focused on treating the causes of com­plex diseases.  Its RestoreU METHOD uses patented artificial-intelligence (AI) software to identify the underlying factors that drive someone’s cognitive decline.  This software generates personalized care plans on how to prevent, slow, or even roll-back the progression of cognitive decline.  The software now identifies all the drugs someone may be taking that increase…READ MORE